Senexis is a small-molecule drug discovery and development company that is committed to revolutionising the treatment and diagnosis of diseases resulting from the inevitable process of ageing. Senexis is advancing a pipeline of novel treatments for diseases resulting from the toxicity of amyloid-like proteins.

Our pipeline is currently focused on discovering potent and selective therapies for the treatment of the following ageing-related diseases:

  • Alzheimer’s disease
  • Inclusion Body Myositis
  • Type 2 diabetes

You can sign up to Senexis news updates here.